The shingles, or herpes zoster, vaccine market is experiencing a growth spurt, driven by a confluence of factors. This market caters to a specific demographic – adults aged 50 and above – who are increasingly susceptible to this painful reactivation of the varicella-zoster virus (VZV), the culprit behind childhood chickenpox. Let's delve deeper and explore the shingles vaccine...
English
Arabic
Français
Español
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian